Ostbye T, Crosse E
Department of Epidemiology and Biostatistics, University of Western Ontario, London.
CMAJ. 1994 Nov 15;151(10):1457-64.
To estimate the net economic costs of dementia in Canada in 1991 by comparing costs related to elderly patients with dementia with those related to elderly people without dementia.
Cost-of-illness study.
Most of the data analysed in this study were from the Canadian Study of Health and Aging (CSHA), in which 10,263 Canadians aged 65 years and over were randomly selected, surveyed and, when appropriate, given clinical examinations. Data on patients with dementia and on people without cognitive impairment (control subjects) were used for this analysis. Data on activities of daily living (ADLs) were taken from a separate study under the CSHA, in which the principal caregivers of the subjects in the prevalence study were interviewed.
Community and institutional settings in Canada, excluding those in the territories.
All patients with dementia 65 years and older as determined from the CSHA. Patients with dementia under 65 were also considered.
Costs of paid and unpaid services in the community, care in long-term care institutions, drugs, hospitalization, diagnosis and research.
The total annual net cost of dementia was estimated to be over $3.9 billion. Costs associated with elderly patients in the community were estimated to be $1.25 billion ($615 million for paid services, $636 million for unpaid services), whereas costs for patients in long-term care institutions were $2.18 billion. Costs were about $74 million for drugs, hospitalization and diagnosis, $10 million for research and $389 million related to patients under age 65.
The annual net economic cost of dementia in Canada is at least $3.9 billion. The most significant component of the total cost was for care in long-term care institutions and for assistance with ADLs by professionals, family and friends in the community. The economic burden of dementia is significant not only for patients, their families and friends, but also for society.
通过比较老年痴呆患者与无痴呆老年人的相关费用,估算1991年加拿大痴呆症的净经济成本。
疾病成本研究。
本研究分析的大部分数据来自加拿大健康与老龄化研究(CSHA),该研究随机选取了10263名65岁及以上的加拿大人进行调查,并在适当的时候进行临床检查。本分析使用了痴呆患者和无认知障碍者(对照对象)的数据。日常生活活动(ADL)数据取自CSHA下的一项单独研究,该研究对患病率研究中的受试者的主要照顾者进行了访谈。
加拿大的社区和机构环境,不包括各地区的环境。
根据CSHA确定的所有65岁及以上的痴呆患者。65岁以下的痴呆患者也在考虑范围内。
社区中付费和无偿服务的费用、长期护理机构的护理费用、药品费用、住院费用、诊断费用和研究费用。
痴呆症的年度总净成本估计超过39亿加元。社区中老年患者的相关费用估计为12.5亿加元(付费服务6.15亿加元,无偿服务6.36亿加元),而长期护理机构患者的费用为21.8亿加元。药品、住院和诊断费用约为7400万加元,研究费用为1000万加元,65岁以下患者的相关费用为3.89亿加元。
加拿大痴呆症的年度净经济成本至少为39亿加元。总成本中最重要的部分是长期护理机构的护理费用以及社区中专业人员、家人和朋友提供的ADL协助费用。痴呆症的经济负担不仅对患者及其家人和朋友来说很大,对社会来说也是如此。